About vaxxinity inc - VAXX
Vaxxinity, Inc. is a biotechnology company that aims to democratize health by bringing the efficiency of vaccines to chronic diseases. The company uses its synthetic peptide vaccine platform to harness the immune system and convert the body into its own 'drug factory', stimulating the production of antibodies with a therapeutic effect. Its current pipeline consists of five chronic disease candidates from early to late-stage development across multiple therapeutic areas including Alzheimer’s, Parkinson’s, migraine and hypercholesterolemia as well as a candidate for COVID-19 prevention. The company was founded by Louis G. Reese IV and Mei Mei Hu in 2014 and is headquartered in Exploration Park, FL.
VAXX At a Glance
Vaxxinity, Inc.
505 Odyssey Way
Exploration Park, Florida 32953
| Phone | 1-245-244-5739 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -56,934,000.00 | |
| Sector | Health Technology | Employees | 57 | |
| Fiscal Year-end | 12 / 2024 | |||
| View SEC Filings |
VAXX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 8.035 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.645 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.165 |
VAXX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -998,842.105 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
VAXX Liquidity
| Current Ratio | 1.888 |
| Quick Ratio | 1.888 |
| Cash Ratio | 1.732 |
VAXX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -75.491 |
| Return on Equity | -150.647 |
| Return on Total Capital | -199.23 |
| Return on Invested Capital | -111.753 |
VAXX Capital Structure
| Total Debt to Total Equity | 113.118 |
| Total Debt to Total Capital | 53.078 |
| Total Debt to Total Assets | 34.198 |
| Long-Term Debt to Equity | 98.904 |
| Long-Term Debt to Total Capital | 46.408 |